Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 331

1.

Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.

Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Meier Y, Larroque S, Roger SD; FIND-CKD Study investigators..

BMC Nephrol. 2017 Jan 17;18(1):24. doi: 10.1186/s12882-017-0444-6.

2.

Na+ deposition in the fibrotic skin of systemic sclerosis patients detected by 23Na-magnetic resonance imaging.

Kopp C, Beyer C, Linz P, Dahlmann A, Hammon M, Jantsch J, Neubert P, Rosenhauer D, Müller DN, Cavallaro A, Eckardt KU, Schett G, Luft FC, Uder M, Distler JH, Titze J.

Rheumatology (Oxford). 2016 Dec 24. pii: kew371. doi: 10.1093/rheumatology/kew371. [Epub ahead of print]

PMID:
28013199
3.

Hypoxia inducible factor stabilization improves defective ischemia-induced angiogenesis in a rodent model of chronic kidney disease.

Schellinger IN, Cordasic N, Panesar J, Buchholz B, Jacobi J, Hartner A, Klanke B, Jakubiczka-Smorag J, Burzlaff N, Heinze E, Warnecke C, Raaz U, Willam C, Tsao PS, Eckardt KU, Amann K, Hilgers KF.

Kidney Int. 2016 Dec 4. pii: S0085-2538(16)30561-0. doi: 10.1016/j.kint.2016.09.028. [Epub ahead of print]

PMID:
27927598
4.

Evaluation of dilution and normalization strategies to correct for urinary output in HPLC-HRTOFMS metabolomics.

Vogl FC, Mehrl S, Heizinger L, Schlecht I, Zacharias HU, Ellmann L, Nürnberger N, Gronwald W, Leitzmann MF, Rossert J, Eckardt KU, Dettmer K, Oefner PJ; GCKD Study Investigators..

Anal Bioanal Chem. 2016 Nov;408(29):8483-8493.

PMID:
27815612
5.

Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer.

Grampp S, Platt JL, Lauer V, Salama R, Kranz F, Neumann VK, Wach S, Stöhr C, Hartmann A, Eckardt KU, Ratcliffe PJ, Mole DR, Schödel J.

Nat Commun. 2016 Oct 24;7:13183. doi: 10.1038/ncomms13183.

6.

C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT).

Mc Causland FR, Claggett B, Burdmann EA, Eckardt KU, Kewalramani R, Levey AS, McMurray JJ, Parfrey P, Remuzzi G, Singh AK, Solomon SD, Toto RD, Pfeffer MA.

Am J Kidney Dis. 2016 Dec;68(6):873-881. doi: 10.1053/j.ajkd.2016.07.022.

PMID:
27646425
7.

Prevalence and Modifiable Determinants of Non-Adherence in Adult Kidney Transplant Recipients in a German Sample.

Reber S, Morawa E, Stößel L, Jank S, Vitinius F, Eckardt KU, Erim Y.

Z Psychosom Med Psychother. 2016 Sep;62(3):270-83. doi: 10.13109/zptm.2016.62.3.270.

PMID:
27594603
8.

Reduction of obliterative bronchiolitis (OB) by prolyl-hydroxylase-inhibitors activating hypoxia-inducible transcription factors in an experimental mouse model.

Heim C, Motsch B, Jalilova S, Bernhardt WM, Ramsperger-Gleixner M, Burzlaff N, Weyand M, Eckardt KU, Ensminger SM.

Transpl Immunol. 2016 Nov;39:66-73. doi: 10.1016/j.trim.2016.08.007.

PMID:
27590486
9.

International Network of Chronic Kidney Disease cohort studies (iNET-CKD): a global network of chronic kidney disease cohorts.

Dienemann T, Fujii N, Orlandi P, Nessel L, Furth SL, Hoy WE, Matsuo S, Mayer G, Methven S, Schaefer F, Schaeffner ES, Solá L, Stengel B, Wanner C, Zhang L, Levin A, Eckardt KU, Feldman HI.

BMC Nephrol. 2016 Sep 2;17(1):121. doi: 10.1186/s12882-016-0335-2.

10.

P2Y2R is a direct target of HIF-1α and mediates secretion-dependent cyst growth of renal cyst-forming epithelial cells.

Kraus A, Grampp S, Goppelt-Struebe M, Schreiber R, Kunzelmann K, Peters DJ, Leipziger J, Schley G, Schödel J, Eckardt KU, Buchholz B.

Purinergic Signal. 2016 Dec;12(4):687-695.

PMID:
27565965
11.

Quantitative assessment of muscle injury by (23)Na magnetic resonance imaging.

Dahlmann A, Kopp C, Linz P, Cavallaro A, Seuss H, Eckardt KU, Luft FC, Titze J, Uder M, Hammon M.

Springerplus. 2016 May 23;5(1):661. doi: 10.1186/s40064-016-2193-6.

12.

Genetic risk variants for membranous nephropathy: extension of and association with other chronic kidney disease aetiologies.

Sekula P, Li Y, Stanescu HC, Wuttke M, Ekici AB, Bockenhauer D, Walz G, Powis SH, Kielstein JT, Brenchley P; GCKD Investigators., Eckardt KU, Kronenberg F, Kleta R, Köttgen A.

Nephrol Dial Transplant. 2016 Feb 4. pii: gfw001. [Epub ahead of print]

PMID:
27333618
13.

Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease - cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort.

Busch M, Nadal J, Schmid M, Paul K, Titze S, Hübner S, Köttgen A, Schultheiss UT, Baid-Agrawal S, Lorenzen J, Schlieper G, Sommerer C, Krane V, Hilge R, Kielstein JT, Kronenberg F, Wanner C, Eckardt KU, Wolf G; GCKD Study Investigators..

BMC Nephrol. 2016 Jun 11;17(1):59. doi: 10.1186/s12882-016-0273-z.

14.

Hepcidin Response to Iron Therapy in Patients with Non-Dialysis Dependent CKD: An Analysis of the FIND-CKD Trial.

Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Bansal SS, Cronin M, Meier Y, Larroque S, Roger SD, Macdougall IC.

PLoS One. 2016 Jun 8;11(6):e0157063. doi: 10.1371/journal.pone.0157063.

15.

Oxalate, inflammasome, and progression of kidney disease.

Ermer T, Eckardt KU, Aronson PS, Knauf F.

Curr Opin Nephrol Hypertens. 2016 Jul;25(4):363-71. doi: 10.1097/MNH.0000000000000229.

PMID:
27191349
16.

Development and validation of cardiovascular risk scores for haemodialysis patients.

Anker SD, Gillespie IA, Eckardt KU, Kronenberg F, Richards S, Drueke TB, Stenvinkel P, Pisoni RL, Robinson BM, Marcelli D, Froissart M, Floege J; On behalf the ARO Steering Committee (collaborators)..

Int J Cardiol. 2016 Aug 1;216:68-77. doi: 10.1016/j.ijcard.2016.04.151.

PMID:
27140339
17.

The impact of hypoxia on nephrogenesis.

Buchholz B, Schley G, Eckardt KU.

Curr Opin Nephrol Hypertens. 2016 May;25(3):180-6. doi: 10.1097/MNH.0000000000000211.

PMID:
27023836
18.

Chronic Kidney Disease (Not) on the Agenda.

Eckardt KU.

Dtsch Arztebl Int. 2016 Feb 12;113(6):83-4. doi: 10.3238/arztebl.2016.0083. No abstract available.

19.

Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice.

Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong AC, Ortiz A, Schaefer F, Torra R, Vanholder R, Więcek A, Zoccali C, Van Biesen W.

Nephrol Dial Transplant. 2016 Mar;31(3):337-48. doi: 10.1093/ndt/gfv456. Review.

20.

Deceased Donor Kidney Transplantation in the Eurotransplant Senior Program (ESP): A Single-Center Experience from 2008 to 2013.

Jacobi J, Beckmann S, Heller K, Hilgers KF, Apel H, Spriewald B, Eckardt KU, Amann KU.

Ann Transplant. 2016 Feb 11;21:94-104.

Items per page

Supplemental Content

Loading ...
Support Center